Researchers at the University of Iowa have developed dual-action nanoparticles that have been shown, in a laboratory study, to selectively kill endometrial cancer (uterine serous carcinoma) cells. The therapeutic approach combines paclitaxel, a common chemo agent, and nintedanib, aka BIBF 1120, a new cancer drug that is typically used to hinder an (Read more...)